Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.

Description: Join us for the It Takes a Village: Insurance Product Development in the Digital webcast. Focuses will be directed toward a variety of disciplines within the actuarial science industry. We will also take a deep dive into UW, Technology Product and Marketing and Distribution. Don't miss the opportunity to bring digital insurance products to life and discover what the process of product evolution.